JERUSALEM, Jan. 9 /PRNewswire-FirstCall/ -- Oramed Pharmaceutical Inc. has added Prof. Itamar Raz to its established scientific advisory board.
Itamar Raz, M.D. is a professor of Internal Medicine at Hadassah University Medical Center and the head of the Diabetes Unit at Hadassah. During 1992-2005 he served as the President of the Israel Diabetes Association. He is the head of the Israel National Council of Diabetes and president of D-Cure, a foundation that supports research in the field of diabetes.
Professor Raz maintains an active clinical research program. He is the director of the newly formed Hadassah Diabetes Research Center, which focuses on experimental and innovative therapies for diabetes and president of the Israel Diabetes Research Group.
He is a member of several editorial boards, including the Israeli Medical Association Journal (IMAJ) and RDS.
“We are pleased that Professor Raz has agreed to join Oramed Pharmaceuticals’ Scientific Advisory Board,” stated Nadav Kidron, CEO of Oramed Pharmaceuticals. “He brings a wealth of knowledge and experience in the field of diabetes therapies to the Company. We believe that Professor Raz’s presence on our Board will help us to advance our research and development of the oral insulin soft gel capsule as well as other products”
Professor Raz has extensively published in the area of diabetes mellitus with over 170 publications to his credit.
His significant contributions to diabetes research will help strengthen the existing Advisory Board as Oramed moves forward with human clinical trials for their insulin soft gel capsule and other developing technologies.
About Oramed Pharmaceuticals, Inc:
Oramed Pharmaceuticals’ is an Israeli based company focused on the development of oral delivery solutions based on proprietary technology. Diabetes is one of the most rapidly growing diseases in the world and is one that requires constant and often unpleasant monitoring and drug therapy regimen. Oramed is currently developing an orally soft gel insulin capsule for the treatment of diabetes. The Company is also pursuing the development of oral delivery solutions for other drugs and vaccines.
For more information on Oramed Pharmaceuticals please visit our website: www.oramedpharma.com
Legal Notice Regarding Forward Looking Statements
This news release contains statements, which may constitute “forward- looking statements”. Those statements include statements regarding the intent, belief or current expectations of Oramed Pharmaceutical Inc., and members of our management as well as the assumptions on which such statements are based. Forward-looking statements in this release include: that we are currently developing an orally ingestible soft gel insulin capsule for the treatment of diabetes and for other diseases. Factors which may significantly change or prevent our forward looking statements from fruition include that oral insulin gel capsules may not be suitable for our intended purposes; we may be unsuccessful in developing any products; we may be unable to raise funds and resources to pursue research and development; we may be unable to successfully defend our patents from infringement by third parties, there is a risk that our patents may be subsequently shown to be invalid or infringe the patents of others, our products may never gain FDA or other regulatory body approval for human consumption and we may be unable to successfully commercialize our future products. Readers should refer to our most recent 10-KSB filed on Edgar.
Oramed Pharmaceutical, Inc.
CONTACT: Investor Relations: Vinisha Agnihotri for Oramed Pharmaceuticals,Inc., +1-646-467-2252, info@oramedpharma.com
Web site: http://www.oramedpharma.com/
